Catalysis deactivated angiotensin-converting enzyme 2 (ACE2) variants and their uses
AssigneeAvirmax, Inc.
InventorShengjiang Liu
Life of this patent
Estimating the term…
Abstract
Angiotensin-converting enzyme 2 (ACE2) has been confirmed as a specific receptor for several (3 group coronaviruses include severe respiratory syndrome (SARS) coronavirus (SARS-CoV-1) and recently the causative agent for the World pandemic CoVID-19, SARS-CoV-2, and low pathogenic coronavirus of HCoV-NL63, a member in α-coronavirus group. Viral spike protein (S) of viral envelope is confirmed to bind to ACE2 as viral receptor to start a virus replication cycle. The present invention provides ACE2 and its mutants or variants, the viral or non-viral vectors thereof. Methods of treatment of viral infection of a human subject by using such mutants or variants are also provided.
Claims19
An isolated angiotensin converting enzyme 2 (ACE2) polypeptide with one or more mutations relative to the wild-type ACE2 that cause the loss of ACE2 enzymatic activity comparing to the wild-type ACE2.
An isolated polynucleotide comprising SEQ ID NOs:
- 64, 66, 67, 68, 69, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80 or 81.
Dependencies are inferred from the claim text.